Amended Termination of Registration of a Class of Security Under Section 12(g) (15-12g/a)
2019年4月3日 - 3:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Amendment No.1
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
|
|
|
Commission
File Number
|
|
000-00935
|
MEDITE Cancer Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
10524 Moss Park Rd. Ste-204-357
Orlando, FL 32832
Telephone: (407) 996-9630
(Address, including zip code, and telephone number, including area
code, of registrant’s principal executive
offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this
Form)
None
(Titles of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file
reports:
|
|
Rule
12g-4(a)(1)
|
☐
|
Rule
12g-4(a)(2)
|
☐
|
Rule
12h-3(b)(1)(i)
|
☐
|
Rule
12h-3(b)(1)(ii)
|
☒
|
Rule
15d-6
|
☐
|
Rule
15d-22(b)
|
☐
|
Approximate
number of holders of record as of the certification or notice
date: 372
EXPLANATORY NOTE
On behalf of MEDITE Cancer Diagnostics, Inc., a Delaware
corporation (“Company”), we hereby request that certain
Form 15-12G filed on March 22, 2019 (“Form 15), be withdrawn
effective immediately. The Company is seeking withdrawal of the
Form 15 because upon further review the Company exceeded
$10,000,000 in total assets on the last days of the last three (3)
consecutive years, respectively, leading up to December 31, 2018,
and it is management’s belief that the Company does not
qualify for the termination of its reporting obligations under Rule
12h-3(b)(1)(ii). The Company is not currently delinquent on any
prior required filings and will resume its reporting obligations
immediately.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this notice to be signed on its behalf
by the undersigned hereunto duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MEDITE Cancer Diagnostics, Inc.
|
|
|
|
|
|
Date:
|
|
April
2, 2019
|
|
|
|
By:
|
|
/s/ Elmar A.
Dave
|
|
|
|
|
|
|
|
|
Name:
|
|
Elmar
A. Dave
|
|
|
|
|
|
|
|
|
Title:
|
|
Chief
Executive Officer and President
|
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
過去 株価チャート
から 11 2024 まで 12 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
過去 株価チャート
から 12 2023 まで 12 2024